HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, J.-G. Articles by Drucker, D. J. Search for Related Content PubMed PubMed Citation Articles by Kim, J.-G. Articles by Drucker, D. J. Social Bookmarking                What's this?

Development and Characterization of a Glucagon-Like Peptide 1-Albumin Conjugate

The Ability to Activate the Glucagon-Like Peptide 1 Receptor In Vivo

¹ Banting and Best Diabetes Centre, Department of Medicine, University of Toronto, Toronto General Hospital, Toronto, Ontario
² Conjuchem, Montreal, Quebec

The rapid degradation of native glucagon-like peptide 1 (GLP-1) by dipeptidyl peptidase-IV (DPP-IV) has fostered new approaches for generation of degradation-resistant GLP-1 analogues. We examined the biological activity of CJC-1131, a DPP-IV-resistant drug affinity complex (DAC) GLP-1 compound that conjugates to albumin in vivo. The CJC-1131 albumin conjugate bound to the GLP-1 receptor (GLP-1R) and activated cAMP formation in heterologous fibroblasts expressing a GLP-1R. CJC-1131 lowered glucose in wild-type mice, but not in GLP-1R-/- mice. Basal glucose and glycemic excursion following glucose challenge remained significantly reduced 10–12 h following a single injection of CJC-1131. Twice daily administration of CJC-1131 to db/db mice significantly reduced glycemic excursion following oral and IP glucose challenge (P < 0.01 to 0.05) but did not significantly lower body weight during the 4-week study period. Levels of random fed glucose were significantly lower in CJC-1131-treated +/+ and db/db mice and remained significantly lower even 1 week following discontinuation of CJC-1131 administration. CJC-1131 increased levels of pancreatic proinsulin mRNA transcripts, percent islet area, and the number of bromodeoxyuridine-positive islet cells. These findings demonstrate that an albumin-conjugated DAC:GLP-1 mimics the action of native GLP-1 and represents a new approach for prolonged activation of GLP-1R signaling.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				B. J. Lamont and D. J. Drucker Differential Antidiabetic Efficacy of Incretin Agonists Versus DPP-4 Inhibition in High Fat Fed Mice Diabetes, January 1, 2008; 57(1): 190 - 198. [Abstract] [Full Text] [PDF]

				G. Flock, L. L. Baggio, C. Longuet, and D. J. Drucker Incretin Receptors for Glucagon-Like Peptide 1 and Glucose-Dependent Insulinotropic Polypeptide Are Essential for the Sustained Metabolic Actions of Vildagliptin in Mice Diabetes, December 1, 2007; 56(12): 3006 - 3013. [Abstract] [Full Text] [PDF]

				T. H Claus, C. Q Pan, J. M Buxton, L. Yang, J. C Reynolds, N. Barucci, M. Burns, A. A Ortiz, S. Roczniak, J. N Livingston, et al. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes J. Endocrinol., February 1, 2007; 192(2): 371 - 380. [Abstract] [Full Text] [PDF]

				L. L. Baggio, D. Holland, J. Wither, and D. J. Drucker Lymphocytic Infiltration and Immune Activation in Metallothionein Promoter-Exendin-4 (MT-Exendin) Transgenic Mice Diabetes, June 1, 2006; 55(6): 1562 - 1570. [Abstract] [Full Text] [PDF]

				M. C. Riddle and D. J. Drucker Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1 Diabetes Care, February 1, 2006; 29(2): 435 - 449. [Full Text] [PDF]

				E. M Sinclair and D. J. Drucker Proglucagon-Derived Peptides: Mechanisms of Action and Therapeutic Potential Physiology, October 1, 2005; 20(5): 357 - 365. [Abstract] [Full Text] [PDF]

				N. Irwin, B. D. Green, M. H. Mooney, B. Greer, P. Harriott, C. J. Bailey, V. A. Gault, F. P. M. O'Harte, and P. R. Flatt A Novel, Long-Acting Agonist of Glucose-Dependent Insulinotropic Polypeptide Suitable for Once-Daily Administration in Type 2 Diabetes J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1187 - 1194. [Abstract] [Full Text] [PDF]

				L. Jette, R. Leger, K. Thibaudeau, C. Benquet, M. Robitaille, I. Pellerin, V. Paradis, P. van Wyk, K. Pham, and D. P. Bridon Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog Endocrinology, July 1, 2005; 146(7): 3052 - 3058. [Abstract] [Full Text] [PDF]

				J. J. Holst and C. Orskov The Incretin Approach for Diabetes Treatment: Modulation of Islet Hormone Release by GLP-1 Agonism Diabetes, December 1, 2004; 53(suppl_3): S197 - S204. [Abstract] [Full Text] [PDF]

				L. L. Baggio, J.-G. Kim, and D. J. Drucker Chronic Exposure to GLP-1R Agonists Promotes Homologous GLP-1 Receptor Desensitization In Vitro but Does Not Attenuate GLP-1R-Dependent Glucose Homeostasis In Vivo Diabetes, December 1, 2004; 53(suppl_3): S205 - S214. [Abstract] [Full Text] [PDF]

				C. F. Deacon Therapeutic Strategies Based on Glucagon-Like Peptide 1 Diabetes, September 1, 2004; 53(9): 2181 - 2189. [Abstract] [Full Text] [PDF]

				L. L. Baggio, Q. Huang, T. J. Brown, and D. J. Drucker A Recombinant Human Glucagon-Like Peptide (GLP)-1-Albumin Protein (Albugon) Mimics Peptidergic Activation of GLP-1 Receptor-Dependent Pathways Coupled With Satiety, Gastrointestinal Motility, and Glucose Homeostasis Diabetes, September 1, 2004; 53(9): 2492 - 2500. [Abstract] [Full Text] [PDF]

				C M. B Edwards GLP-1: target for a new class of antidiabetic agents? J R Soc Med, June 1, 2004; 97(6): 270 - 274. [Full Text] [PDF]

				P. L. Brubaker and D. J. Drucker Minireview: Glucagon-Like Peptides Regulate Cell Proliferation and Apoptosis in the Pancreas, Gut, and Central Nervous System Endocrinology, June 1, 2004; 145(6): 2653 - 2659. [Abstract] [Full Text] [PDF]

				T. Hansotia, L. L. Baggio, D. Delmeire, S. A. Hinke, Y. Yamada, K. Tsukiyama, Y. Seino, J. J. Holst, F. Schuit, and D.J. Drucker Double Incretin Receptor Knockout (DIRKO) Mice Reveal an Essential Role for the Enteroinsular Axis in Transducing the Glucoregulatory Actions of DPP-IV Inhibitors Diabetes, May 1, 2004; 53(5): 1326 - 1335. [Abstract] [Full Text] [PDF]

				J. J. Meier, M. A. Nauck, D. Kranz, J. J. Holst, C. F. Deacon, D. Gaeckler, W. E. Schmidt, and B. Gallwitz Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects Diabetes, March 1, 2004; 53(3): 654 - 662. [Abstract] [Full Text] [PDF]

				D. J. Drucker Glucagon-Like Peptide-1 and the Islet {beta}-Cell: Augmentation of Cell Proliferation and Inhibition of Apoptosis Endocrinology, December 1, 2003; 144(12): 5145 - 5148. [Full Text] [PDF]

				D. J. Drucker Enhancing Incretin Action for the Treatment of Type 2 Diabetes Diabetes Care, October 1, 2003; 26(10): 2929 - 2940. [Abstract] [Full Text] [PDF]

				H. Yamamoto, T. Kishi, C. E. Lee, B. J. Choi, H. Fang, A. N. Hollenberg, D. J. Drucker, and J. K. Elmquist Glucagon-Like Peptide-1-Responsive Catecholamine Neurons in the Area Postrema Link Peripheral Glucagon-Like Peptide-1 with Central Autonomic Control Sites J. Neurosci., April 1, 2003; 23(7): 2939 - 2946. [Abstract] [Full Text] [PDF]